RESUMEN
BACKGROUND: This systematic review aims to assess the efficacy and safety of transsphenoidal surgery (TPS) for patients with a pituitary tumor (PT). METHODS: We will retrieve the following electronic databases for randomized controlled trials or case-control studies to assess the effect and safety of TPS for PT: Cochrane Library, EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database. Each database will be retrieved from the inception to December 20, 2018. The entire process consists of the study selection, data collection, methodology quality assessment, data pooled, and meta-analysis performance. The methodology quality will be assessed by using Cochrane risk of bias tool. The data pooled and meta-analysis will be conducted by using RevMan 5.3 software. RESULTS: This study will evaluate the efficacy and safety of TPS for PT. The primary outcome includes total tumor resection rate. The secondary outcomes consist of quality of life, total tumor resection rate, postoperative complication rate, and the rate of functional tumor hormone levels. CONCLUSION: The expected results may provide up-to-date evidence of TPS for the treatment of PT. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42018120194.
Asunto(s)
Neoplasias Hipofisarias/cirugía , Proyectos de Investigación , Seno Esfenoidal , Estudios de Casos y Controles , Humanos , Hormonas Hipofisarias/sangre , Complicaciones Posoperatorias/epidemiología , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
In developed, developing and low-income countries alike, type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases, the severity of which is substantially a consequence of multiple organ complications that occur due to long-term progression of the disease before diagnosis and treatment. Despite enormous investment into the characterization of the disease, its long-term management remains problematic, with those afflicted enduring significant degradation in quality-of-life. Current research efforts into the etiology and pathogenesis of T2DM, are focused on defining aberrations in cellular physiology that result in development of insulin resistance and strategies for increasing insulin sensitivity, along with downstream effects on T2DM pathogenesis. Ongoing use of plant-derived naturally occurring materials to delay the onset of the disease or alleviate symptoms is viewed by clinicians as particularly desirable due to well-established efficacy and minimal toxicity of such preparations, along with generally lower per-patient costs, in comparison to many modern pharmaceuticals. A particularly attractive candidate in this respect, is fenugreek, a plant that has been used as a flavouring in human diet through recorded history. The present study assessed the insulin-sensitizing effect of fenugreek seeds in a cohort of human volunteers, and tested a hypothesis that melanin-concentrating hormone (MCH) acts as a critical determinant of this effect. A test of the hypothesis was undertaken using a hyperinsulinemic euglycemic glucose clamp approach to assess insulin sensitivity in response to oral administration of a fenugreek seed preparation to healthy subjects. Outcomes of these evaluations demonstrated significant improvement in glucose tolerance, especially in patients with impaired glucose responses. Outcome data further suggested that fenugreek seed intake-mediated improvement in insulin sensitivity correlated with reduction in MCH levels.
Asunto(s)
Hipoglucemiantes/farmacología , Hormonas Hipotalámicas/sangre , Insulina/metabolismo , Melaninas/sangre , Hormonas Hipofisarias/sangre , Extractos Vegetales/farmacología , Trigonella/química , Adulto , Femenino , Humanos , Hipoglucemiantes/administración & dosificación , Resistencia a la Insulina , Masculino , Persona de Mediana Edad , Extractos Vegetales/administración & dosificación , Semillas/químicaRESUMEN
The Uniform Determination of Death Act (UDDA) states that an individual is dead when "all functions of the entire brain" have ceased irreversibly. However, it has been questioned whether some functions of the hypothalamus, particularly osmoregulation, can continue after the clinical diagnosis of brain death (BD). In order to learn whether parts of the hypothalamus can continue to function after the diagnosis of BD, we performed 2 separate systematic searches of the MEDLINE database, corresponding to the functions of the posterior and anterior pituitary. No meta-analysis is possible due to nonuniformity in the clinical literature. However, some modest generalizations can reasonably be drawn from a narrative review and from anatomic considerations that explain why these findings should be expected. We found evidence suggesting the preservation of hypothalamic function, including secretion of hypophysiotropic hormones, responsiveness to anterior pituitary stimulation, and osmoregulation, in a substantial proportion of patients declared dead by neurological criteria. We discuss several possible explanations for these findings. We conclude by suggesting that additional clinical research with strict inclusion criteria is necessary and further that a more nuanced and forthright public dialogue is needed, particularly since standard diagnostic practices and the UDDA may not be entirely in accord.
Asunto(s)
Daño Encefálico Crónico/patología , Daño Encefálico Crónico/fisiopatología , Muerte Encefálica/fisiopatología , Hormonas Hipotalámicas/sangre , Hipotálamo/patología , Hipófisis/patología , Hormonas Hipofisarias/sangre , Muerte Encefálica/patología , Hormona Liberadora de Corticotropina/sangre , Hormona Liberadora de Gonadotropina/sangre , Hormona Liberadora de Hormona del Crecimiento/sangre , Humanos , Sistema Hipotálamo-Hipofisario/fisiopatología , Cuidados para Prolongación de la VidaRESUMEN
BACKGROUND: In preclinical studies, the hypothalamic polypeptide melanin-concentrating hormone (MCH) has been shown to be involved in depression-like behavior and modulations of MCH and MCH-receptors were proposed as potential new antidepressant drug targets. METHODS: For the first time, MCH serum levels were explored in 30 patients with major depressive disorder (MDD) prior to (T1) and after 2 (T2) and 4 weeks (T3) of antidepressant treatment and in 30 age- and sex-matched healthy controls by applying a fluorescence immunoassay. RESULTS: Levels of MCH did not differ significantly between un-medicated patients (444.11±174.63pg/mL SD) and controls (450.68±210.03pg/mL SD). In MDD patients, MCH levels significantly decreased from T1 to T3 (F=4.663; p=0.013). Post-hoc analyses showed that these changes were limited to patients treated with mirtazapine but not escitalopram and female but not male patients. MCH-levels showed high correlations from T1 to T3 (r≥0.964, p<0.001) and were found to correlate significantly with parameters of sleep within the controls. LIMITATIONS: Small sample size. No follow-up measures were performed within the control group. CONCLUSIONS: Our findings suggest peripheral MCH-levels not to be altered in depression but possibly reflecting depression-related state properties that can be modulated by sleep, medication and sex.
Asunto(s)
Antidepresivos/administración & dosificación , Trastorno Depresivo Mayor/tratamiento farmacológico , Hormonas Hipotalámicas/sangre , Melaninas/sangre , Hormonas Hipofisarias/sangre , Adulto , Antidepresivos/farmacología , Citalopram/administración & dosificación , Trastorno Depresivo Mayor/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hipotálamo/efectos de los fármacos , Masculino , Mianserina/administración & dosificación , Mianserina/análogos & derivados , Mirtazapina , Factores Sexuales , Resultado del TratamientoRESUMEN
CONTEXT: Mutations within the PROP1 gene represent one of the main causes of familial combined pituitary hormone deficiency (CPHD). However, most of the cases are sporadic with an unknown genetic cause. OBJECTIVE: The aim of this study was the search for low penetrance variations within and around a conserved regulatory element in the intron 1 of PROP1, contributing to a multifactorial form of the disease in sporadic patients. METHODS AND PATIENTS: A fragment of 570 bp encompassing the conserved region was sequenced in 107 CPHD patients and 294 controls, and an association study was performed with the four identified variants, namely c.109+435G>A (rs73346254), c.109+463C>T (rs4498267), c.109+768C>G (rs4431364), and c.109+915_917ins/delTAG (rs148607624). The functional role of the associated polymorphisms was evaluated by luciferase reporter gene expression analyses and EMSA. RESULTS: A statistically significant increased frequency was observed in the patients for rs73346254A (P = 5 × 10(-4)) and rs148607624delTAG (P = 0.01) alleles. Among all the possible allele combinations, only the haplotype bearing both risk alleles showed a significantly higher frequency in the patients vs. controls (P = 4.7 × 10(-4)) and conferred a carrier risk of 4.19 (P = 1.2 × 10(-4)). This haplotype determined a significant decrease of the luciferase activity in comparison with a basal promoter and the other allelic combinations in GH4C and MCF7 cells (P = 4.6 × 10(-6); P = 5.5 × 10(-4), respectively). The EMSA showed a differential affinity for nuclear proteins for the alternative alleles of the two associated variations. CONCLUSIONS: Variations with a functional significance conferring susceptibility to CPHD have been identified in the PROP1 gene, indicating a multifactorial origin of this disorder in sporadic cases.
Asunto(s)
Proteínas de Homeodominio/genética , Hormona de Crecimiento Humana/deficiencia , Adolescente , Edad de Inicio , Células Cultivadas , Niño , Preescolar , Secuencia Conservada , Ensayo de Cambio de Movilidad Electroforética , Femenino , Variación Genética , Vectores Genéticos , Hormonas/sangre , Humanos , Hipotálamo/patología , Lactante , Factor I del Crecimiento Similar a la Insulina/deficiencia , Intrones/genética , Luciferasas/genética , Imagen por Resonancia Magnética , Masculino , Mutación/genética , Mutación/fisiología , Penetrancia , Hipófisis/patología , Hormonas Hipofisarias/sangre , Polimorfismo de Nucleótido Simple/genética , Transfección , Adulto JovenRESUMEN
OBJECT: Causes of pituitary insufficiencies as a side effect of Gamma Knife surgery (GKS) following irradiation of the hypothalamopituitary axis are still under debate. In an investigation of pituitary insufficiencies after GKS, the authors' main focus is on what role can be attributed to the hypothalamus with regard to endocrinological changes in hypothalamopituitary function following GKS. METHODS: A total of 108 patients consecutively treated between April 1992 and July 2003 were included in this retrospective study. All patients had undergone either transsphenoidal or transcranial surgery prior to GKS. The spot dosimetry method was used to determine doses delivered to structures of the hypothalamopituitary axis. For statistical analyses, endocrine insufficiency and deterioration in pituitary function were defined as a decrease in hormonal blood levels below the normal range for 1 or more anterior pituitary lobe hormones. Additionally, an analysis of the rate of patients requiring hormone replacement therapy after GKS due to new endocrinopathies was performed. RESULTS: Complete patient records of 61 male and 47 female patients with a mean age of 51.9 years (range 9.181.2 years) were available for our investigation. The overall tumor control rate was 97% and the endocrinological cure rate was 61.2%. Mean treatment doses in patients with and without new endocrine insufficiencies (shown as with/without insufficiencies and followed by probability values) were as follows: 1.3/0.8 Gy to the hypothalamus(p = 0.2); 2.2/1.6 Gy to the median eminence (p = 0.1); 6.5/4.1 Gy to the pituitary stalk (p = 0.004); and 12.4/9.5Gy to the pituitary gland (p = 0.05). The median overall duration of follow-up after GKS was 6.7 years, with 84 patients(77.7%) whose follow-up was longer than 12 months. The median follow-up time after GKS in patients who developed a new pituitary dysfunction was 79.5 months (6.6 years, SD 3.8 years), and the median follow-up time inpatients with no new insufficiencies was 78.4 months (6.5 years, SD 4 years). CONCLUSIONS: Gamma Knife surgery is a safe and effective treatment for patients with residual and recurrent pituitary adenomas. The rate of pituitary insufficiencies after GKS is still lower than that after conventional radiotherapy.Very low radiation doses are directed to the hypothalamus, and thus this structure does not play a major role in the development of pituitary insufficiencies after GKS. The results of this study show that patients in whom the pituitary stalk and pituitary gland receive a high mean point dose are more likely to develop pituitary insufficiencies after GKS than those who receive a lower dose. (DOI: 10.3171/2010.8.GKS10959).
Asunto(s)
Hipopituitarismo/etiología , Hipopituitarismo/metabolismo , Hipotálamo/fisiología , Hipotálamo/efectos de la radiación , Hormonas Hipofisarias/sangre , Neoplasias Hipofisarias/cirugía , Complicaciones Posoperatorias/metabolismo , Radiocirugia/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Relación Dosis-Respuesta en la Radiación , Femenino , Estudios de Seguimiento , Humanos , Sistema Hipotálamo-Hipofisario/metabolismo , Sistema Hipotálamo-Hipofisario/fisiopatología , Sistema Hipotálamo-Hipofisario/efectos de la radiación , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/epidemiología , Hipófisis/efectos de la radiación , Radiometría , Adulto JovenRESUMEN
CONTEXT: The classical interpretation of the feedback regulation of the male hypothalamo-pituitary-gonadal axis predicts that a partial inhibition of testosterone (T) synthesis will result in a compensatory rise in LH secretion. The question arises as to whether such a compensation is complete or that decreased T synthesis may result in a lower plasma T concentration. OBJECTIVE: To investigate whether a moderate inhibition of T synthesis capacity will be fully compensated by increased LH secretion. DESIGN, SUBJECTS AND INTERVENTIONS: In nine young healthy men, we partially inhibited T synthesis capacity using ketoconazole (KTZ) 100 mg four times daily. On day -6 (1 week prior to KTZ intake), days 1 and 8 of KTZ administration blood was drawn [07:00 h (t(1)), 10:00 h (t(2)), 13:00 h (t(3))] for evaluation of T, LH, oestradiol (E2), 17-OH-progesterone (17OHP), progesterone (PR) and sex hormone binding globulin (SHBG). On day 8, 5000 IU of hCG were administered to evaluate the maximal T secretion under KTZ. RESULTS: Administration of KTZ resulted in an acute, moderate but significant decrease of plasma T concentration. On day 8, plasma LH, 17OHP and PR were elevated relative to day -6 and day 1, but mean T was still lower compared to day -6. Mean E2 and SHBG were only slightly affected by KTZ. After stimulation by hCG, plasma T was restored to its baseline level. CONCLUSION: These results argue against the assumption that a moderate decline in T synthesis capacity will be compensated completely by increased LH secretion.
Asunto(s)
Hipotálamo/efectos de los fármacos , Cetoconazol/farmacología , Hipófisis/efectos de los fármacos , Esteroide 17-alfa-Hidroxilasa/antagonistas & inhibidores , Testosterona/biosíntesis , Adulto , Antagonistas de Andrógenos/administración & dosificación , Antagonistas de Andrógenos/efectos adversos , Antagonistas de Andrógenos/farmacología , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/fisiología , Esquema de Medicación , Estradiol/sangre , Retroalimentación Fisiológica/efectos de los fármacos , Humanos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/metabolismo , Hipotálamo/metabolismo , Cetoconazol/administración & dosificación , Cetoconazol/efectos adversos , Masculino , Hipófisis/metabolismo , Hormonas Hipofisarias/sangre , Globulina de Unión a Hormona Sexual/análisis , Testosterona/antagonistas & inhibidores , Testosterona/sangre , Adulto JovenRESUMEN
Prolactinomas are the most prevalent functional pituitary adenomas. Dopamine D2 receptor (D2R) agonists, such as bromocriptine are the first line of therapy; however, drug intolerance/resistance to D2R agonists exists. Apart from D2R agonists, there is no established medical therapy for prolactinomas; therefore, identifying novel therapeutics is warranted. Curcumin, a commonly used food additive in South Asian cooking, inhibits proliferation of several tumor cell lines; however, its effect on pituitary tumor cell proliferation has not been determined. Our objectives were to: 1) determine whether curcumin inhibits proliferation of pituitary tumor cell lines; 2) identify the signaling intermediaries that mediate the effect of curcumin; 3) examine whether curcumin inhibited pituitary hormone production and release; and 4) examine whether curcumin could enhance the growth-inhibitory effect of bromocriptine. Using rat lactotroph cell lines, GH3 and MMQ cells, we report that curcumin had a robust dose and time-dependent inhibitory effect on GH3 and MMQ cell proliferation. Inhibitory effects of curcumin persisted, even on removal of curcumin, and curcumin also blocked colony formation ability of pituitary tumor cells. The growth-inhibitory effect of curcumin was accompanied by decreased expression of cyclin D3 and ser 780 phosphorylation of retinoblastoma protein. In addition, curcumin also induced apoptosis in both GH3 and MMQ cells. Furthermore, curcumin suppresses intracellular levels and release of both prolactin and GH. Finally, we show that low concentrations of curcumin enhanced the growth-inhibitory effect of bromocriptine on MMQ cell proliferation. Taken together we demonstrate that curcumin inhibits pituitary tumor cell proliferation, induces apoptosis, and decreases hormone production and release, and thus, we propose developing curcumin as a novel therapeutic tool in the management of prolactinomas.
Asunto(s)
Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Curcumina/farmacología , Hormonas Hipofisarias/metabolismo , Neoplasias Hipofisarias/metabolismo , Prolactinoma/metabolismo , Animales , Antineoplásicos/farmacología , Bromocriptina/farmacología , Células Clonales/efectos de los fármacos , Ciclina D3 , Ciclinas/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Fosforilación/efectos de los fármacos , Hormonas Hipofisarias/sangre , Neoplasias Hipofisarias/sangre , Prolactinoma/sangre , Ratas , Proteína de Retinoblastoma/metabolismo , Factores de Tiempo , Células Tumorales CultivadasRESUMEN
OBJECTIVE: While anti-pituitary antibodies (APAs) were detected in some patients with Sheehan's syndrome (SS) suggesting an autoimmune pituitary involvement in the development of their hypopituitarism, hypothalamic cell anti-hypothalamus antibodies (AHAs) have not been investigated so far. DESIGN: The aim of this study was to evaluate the presence of AHA and APA in SS patients to verify whether an autoimmune hypothalamic-pituitary process can contribute to their late hypopituitarism. METHODS: Twenty women with SS with a duration of disease ranging from 3 to 40 years (median 25.5 years) were enrolled into the study. Out of 20 patients, 12 (60%) had panhypopituitarism and the others had partial hypopituitarism well corrected with appropriate replacement therapy. None of them had clinical central diabetes insipidus. AHA and APA were investigated by immunofluorescence method in all patients. In addition, a four-layer immunofluorescence method was used to verify whether AHA immunostained vasopressin-secreting cells (AVP-c) or not. RESULTS: AHAs were found in 8 out of 20 (40%) and APAs in 7 out of 20 (35%) patients with titers ranging from 1:32 to 1:128 and 1:16 to 1:32 respectively; however, in none of these positive patients AHA immunostained vasopressin cells. None of controls resulted positive for both antibodies. CONCLUSIONS: Patients with SS, even many years after the onset of SS, can show antibodies to pituitary and/or hypothalamic but not AVP-secreting cells. Antibodies to unknown hypothalamic cells (releasing factor-secreting cells) other than APAs suggest that an autoimmune process involving both the hypothalamus and pituitary gland may contribute to late pituitary dysfunction in SS patients.
Asunto(s)
Autoanticuerpos/sangre , Síndrome de Silla Turca Vacía/complicaciones , Hipopituitarismo/inmunología , Hipotálamo/inmunología , Hipófisis/inmunología , Adulto , Anciano , Autoinmunidad , Estudios de Casos y Controles , Síndrome de Silla Turca Vacía/inmunología , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Hipopituitarismo/sangre , Hipopituitarismo/patología , Imagen por Resonancia Magnética , Persona de Mediana Edad , Hipófisis/patología , Hormonas Hipofisarias/administración & dosificación , Hormonas Hipofisarias/sangre , Síndrome , Factores de TiempoRESUMEN
Reports have shown that soybeans are goitrogenic. In the present study, we investigated the effects of a high soybean diet in rats that were fed normal or iodine-deficient chow on the regulation of anterior pituitary hormone production. Iodine deficiency alone resulted in thyroid hyperplasia, reduced serum thyroxine levels, and a tendency towards an increase in serum thyroid stimulating hormone (TSH). The combination of a high soybean and low iodine diet (ID + DS) acted synergistically to induce thyroid hypertrophy, reduce serum thyroxine and tri-iodothyronine, and markedly increase serum TSH. Immunohistochemical analysis revealed that rats fed the ID + DS diet exhibited a marked increase in their number of pituitary TSH, prolactin (PRL), and growth hormone (GH) producing cells. Pituitary transcription factor-1 (Pit-1) which is involved in the expression of the TSH, PRL, and GH genes was also increased in ID + DS fed rats. These results suggest that a diet high in soybean products modulates anterior pituitary hormone production by regulating Pit-1 induction, in iodine-deficient animals.
Asunto(s)
Dieta , Yodo/deficiencia , Hormonas Hipofisarias/biosíntesis , Proteínas de Soja/administración & dosificación , Proteínas de Soja/farmacología , Factor de Transcripción Pit-1/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Femenino , Hipotálamo/citología , Hipotálamo/efectos de los fármacos , Immunoblotting , Inmunohistoquímica , Tamaño de los Órganos/efectos de los fármacos , Hipófisis/citología , Hipófisis/efectos de los fármacos , Hipófisis/ultraestructura , Hormonas Hipofisarias/sangre , Ratas , Glándula Tiroides/citología , Glándula Tiroides/efectos de los fármacos , Hormonas Tiroideas/sangre , Hormona Liberadora de Tirotropina/metabolismoRESUMEN
This study evaluated basal levels and responsiveness to exercise of plasma adrenocorticotropic hormone (ACTH), and serum thyroid stimulating hormone (TSH), growth hormone (GH) and cortisol among adolescents from two differentially exposed groups 6 1/2 years after the 1988 earthquake in Armenia. Severity of total PTSD and Category C and D symptoms were negatively correlated with baseline cortisol. Preexercise ACTH was significantly lower, and preexercise TSH higher, among adolescents with more exposure. Depressive symptoms were negatively correlated with baseline cortisol and positively with TSH. Mean GH, TSH, and cortisol levels in both groups fell within normal limits. The pre- to postexercise increase in GH, TSH, and cortisol suggests that exercise challenge may be useful in the field investigation of neurohormonal activity among traumatized individuals.
Asunto(s)
Sistema Hipotálamo-Hipofisario/metabolismo , Hipotálamo/metabolismo , Sistema Hipófiso-Suprarrenal/metabolismo , Trastornos por Estrés Postraumático/metabolismo , Adolescente , Hormona Adrenocorticotrópica/sangre , Armenia , Desastres , Ejercicio Físico , Femenino , Humanos , Hidrocortisona/sangre , Masculino , Hormonas Hipofisarias/sangre , Trastornos por Estrés Postraumático/sangre , Trastornos por Estrés Postraumático/psicologíaRESUMEN
Although women constitute the majority of patients who receive treatment with selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, most animal studies of SSRIs are conducted on males. The present study investigated whether long-term treatment of cycling female rats with fluoxetine alters their estrous cycle and the sensitivity of hypothalamic serotonin (5-HT) 5-HT(1A) and 5-HT(2A) receptor systems. Adult female rats received daily injections of fluoxetine (10 mg/kg, i.p.) for three consecutive estrous cycles (15.2+/-0.2 days) with the first injection beginning on metestrus (when circulating estrogen levels are low and stable). Fluoxetine did not alter basal plasma estradiol levels at metestrus, nor did it alter the pattern of estrous cyclicity. Rats treated with fluoxetine showed a loss in body weight. On the morning of metestrus of the fourth cycle (18 h after the last fluoxetine injection), the rats were injected with a sub-maximal dose of the 5-HT(1A) agonist (+/-)-8-hydroxy-2-dipropylaminotetralin (8-OH-DPAT, 50 MICRO/kg, s.c.) or a maximal dose of the 5-HT(2A) agonist [(+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] (DOI). Plasma levels of oxytocin, ACTH and corticosterone were measured as peripheral indicators of hypothalamic 5-HT(1A) and 5-HT(2A) receptor sensitivity. Injecting 8-OH-DPAT to saline pretreated rats produced a significant increase in plasma oxytocin (299%), ACTH (1456%) and corticosterone (170%) levels but not in plasma prolactin or renin concentrations. Greater increases in plasma levels of these hormones were observed after injecting DOI. Fluoxetine treatment completely blocked the oxytocin, ACTH and corticosterone responses to 8-OH-DPAT, but did not inhibit the effect of DOI on any hormone, thus confirming that fluoxetine treatment did not produce a deficit in the functioning of corticotropin releasing hormone or oxytocin containing neurons. These results indicate that in cycling female rats, fluoxetine treatment desensitizes hypothalamic post-synaptic 5-HT(1A) receptor signaling. Understanding the pharmacological effects of fluoxetine in females may lead to more effective treatment of women with mood disorders.
Asunto(s)
Antidepresivos de Segunda Generación/farmacología , Fluoxetina/farmacología , Hipotálamo/efectos de los fármacos , Receptores de Serotonina/efectos de los fármacos , 2,5-Dimetoxi-4-Metilanfetamina/farmacología , 8-Hidroxi-2-(di-n-propilamino)tetralin/farmacología , Análisis de Varianza , Animales , Peso Corporal/efectos de los fármacos , Corticosterona/sangre , Interacciones Farmacológicas , Ciclo Estral/efectos de los fármacos , Ciclo Estral/metabolismo , Femenino , Hipotálamo/metabolismo , Hormonas Hipofisarias/sangre , Ratas , Ratas Sprague-Dawley , Receptor de Serotonina 5-HT2A , Receptores de Serotonina/metabolismo , Receptores de Serotonina 5-HT1 , Agonistas de Receptores de Serotonina/farmacologíaRESUMEN
Apelin is the recently identified endogenous ligand for the G-protein-coupled receptor, APJ. Preproapelin and APJ mRNA are found in hypothalamic regions known to be important in the regulation of food and water intake, and pituitary hormone release. The effects of intracerebroventricular (ICV) administration of pyroglutamylated apelin-13 on food and water intake and pituitary hormone release in rats were investigated. Apelin-13 had little effect on food intake, but dose-dependently increased drinking behaviour and water intake at 1 h. Apelin-13 (10 nmol) increased water intake by up to sixfold compared to saline. Compared to saline control, apelin-13 (10 nmol) significantly increased plasma ACTH and corticosterone and decreased plasma prolactin, LH and FSH at 30 min. In vitro, apelin-13 stimulated the release of CRH and AVP from hypothalamic explants, but had no effect on NPY release. These results suggest that apelin may play an important role in the hypothalamic regulation of water intake and endocrine axes.
Asunto(s)
Proteínas Portadoras/farmacología , Ingestión de Líquidos/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Hormonas Hipofisarias/metabolismo , Animales , Apelina , Arginina Vasopresina/metabolismo , Corticosterona/sangre , Hormona Liberadora de Corticotropina/metabolismo , Conducta de Ingestión de Líquido , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Péptidos y Proteínas de Señalización Intercelular , Masculino , Modelos Animales , Neuropéptido Y/metabolismo , Péptidos/farmacología , Hormonas Hipofisarias/sangre , Ratas , Ratas WistarRESUMEN
A deficiency of dietary selenium leads to immotile, deformed sperm and infertility in rats, whereas supplementation of the diet with selenium compounds has been associated with both beneficial and deleterious effects on sperm function, depending on the chemical form of selenium. We conducted a randomized, controlled, and blinded intervention study on the effects of selenium in food on semen quality. Eleven healthy men were fed a controlled diet of foods naturally high or low in selenium for 120 days while confined in a metabolic research unit. Dietary selenium was 47 microg/d for the first 21 days, then either 13 microg/d or 297 microg/d for 99 days, resulting in significant changes in selenium concentrations in blood and semen. Seminal plasma selenium concentration increased 50% with high selenium and decreased 40% with low selenium. The fraction of motile sperm in the high-selenium group decreased by 32% by week 13 and ended 18% lower than baseline. Selenium concentrations changed in seminal plasma but not in sperm, and serum androgen concentrations were unchanged in both groups, indicating this effect was neither androgen dependent nor caused by a change in the selenium supply to the testes. Serum triiodothyronine decreased and thyroid-stimulating hormone increased in the high-selenium group, suggesting that altered thyroid hormone metabolism may have affected sperm motility. Although this decrease in sperm motility does not necessarily predict decreased fertility, the increasing frequency of selenium supplementation in the healthy population suggests the need for larger studies to more fully assess this potential side effect.
Asunto(s)
Suplementos Dietéticos , Selenio/farmacología , Motilidad Espermática/efectos de los fármacos , Hormonas Esteroides Gonadales/sangre , Humanos , Masculino , Hormonas Hipofisarias/sangre , Valores de Referencia , Selenio/análisis , Selenio/sangre , Semen , Triyodotironina/sangreRESUMEN
BACKGROUND: Repetitive transcranial magnetic stimulation (rTMS) is a new therapeutic tool in the treatment of affective disorders but only few studies on its safety exist. We aimed to determine the impact of rTMS on (neuro)endocrinological serum levels by a placebo-controlled cross-over study. METHODS: 23 healthy subjects were stimulated by rTMS in a typical paradigm used in the treatment of depression (coil placed over left dorsolateral prefrontal cortex, 10 and 20 Hz stimulation). Placebo, infrathreshold, and suprathreshold stimulation were applied in random order. The serum levels of cortisol, prolactin, FSH, and TSH were measured before and after stimulation. RESULTS: After infrathreshold stimulation, cortisol and TSH serum levels decreased mildly but significantly. All other stimulations had no significant impact on hormone levels. In female, but not in male, subjects placebo stimulation yielded a significant increase of prolactin. CONCLUSIONS: rTMS as applied for the treatment of depression leads to only very mild and safe changes of hormones. These changes, in particular the decrease of cortisol levels, might explain in part the efficacy of rTMS.
Asunto(s)
Afecto/fisiología , Terapia por Estimulación Eléctrica , Campos Electromagnéticos , Lóbulo Frontal/fisiología , Hidrocortisona/sangre , Hormonas Hipofisarias/sangre , Adulto , Estudios Cruzados , Dominancia Cerebral/fisiología , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Masculino , Persona de Mediana Edad , Prolactina/sangre , Valores de Referencia , Método Simple Ciego , Tirotropina/sangreRESUMEN
Cocaine- and amphetamine-regulated transcript (CART) and CART peptide are abundant in hypothalamic nuclei controlling anterior pituitary function. Intracerebroventricular (ICV) injection of CART peptide results in neuronal activation in the paraventricular nucleus (PVN), rich in corticotrophin-releasing factor (CRH) and thyrotrophin-releasing factor (TRH) immunoreactive neurons. The aims of this study were three-fold. Firstly, to examine the effects of CART peptide on hypothalamic releasing factors in vitro, secondly, to examine the effect of ICV injection of CART peptide on plasma pituitary hormones and finally to examine the effect of PVN injection of CART peptide on food intake and circulating pituitary hormones. CART(55-102) (100 nM) peptide significantly stimulated the release of CRH, TRH and neuropeptide Y from hypothalamic explants but significantly reduced alpha melanocyte stimulating hormone release in vitro. Following ICV injection of 0.2 nmol CART(55-102), a dose which significantly reduces food intake, plasma prolactin (PRL), growth hormone (GH) and adrenocorticotrophin hormone (ACTH) and corticosterone increased significantly. Following PVN injection of CART(55-102), food intake was significantly reduced only at 0.2 and 0.6 nmol. However, PVN injection of 0.02 nmol CART(55-102) produced a significant increase in plasma ACTH. ICV injection of CART peptide significantly reduces food intake. Unlike many anorexigenic peptides, there is no increased sensitivity to PVN injection of CART(55-102). In contrast, both ICV and PVN injection of CART(55-102) significantly increased plasma ACTH and release of hypothalamic CRH is significantly increased by CART peptide in vitro. This suggests that CART peptide may play a role in the control of pituitary function and in particular the hypothalamo-pituitary adrenal axis.
Asunto(s)
Regulación del Apetito/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Proteínas del Tejido Nervioso/administración & dosificación , Animales , Hormona Liberadora de Corticotropina/metabolismo , Glucosa/administración & dosificación , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Técnicas In Vitro , Inyecciones Intraventriculares , Masculino , Microinyecciones , Proteínas del Tejido Nervioso/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuropéptido Y/metabolismo , Neuropéptidos/metabolismo , Núcleo Hipotalámico Paraventricular/citología , Núcleo Hipotalámico Paraventricular/efectos de los fármacos , Núcleo Hipotalámico Paraventricular/metabolismo , Fragmentos de Péptidos/administración & dosificación , Hormonas Hipofisarias/sangre , Ratas , Ratas Wistar , Proteínas Recombinantes/administración & dosificación , Organismos Libres de Patógenos Específicos , Hormona Liberadora de Tirotropina/metabolismoRESUMEN
The effect of melatonin injection on Freund's adjuvant-induced changes in levels and 24-hr rhythms of circulating ACTH, growth hormone (GH), prolactin (PRL), luteinizing hormone (LH), and insulin was assessed in rats. Animals received subcutaneous (s.c.) injections of melatonin (30 microg) or vehicle, 1 hr before lights off for 12 days. Ten days after melatonin treatment, they were injected with Freund's complete adjuvant or its vehicle s.c., and after 3 days, rats were killed at six different time intervals throughout a 24-hr cycle to measure the different hormones by radioimmunoassay (RIA). Following Freund's adjuvant injection, an increase in serum ACTH, with maintenance of ACTH diurnal rhythm was found. Acrophases of the ACTH rhythm varied from 13:39 to 17:12 hr and the amplitude of rhythm was augmented after immunization. In immunized rats, melatonin treatment increased the amplitude of serum ACTH rhythm. For GH, a depressive effect of immunization on circulating levels, together with absence of diurnal rhythmicity were found. Immunization augmented circulating PRL, while conserving its diurnal rhythmicity. Melatonin-injected rats showed significant diurnal variations of serum PRL after immunization only. Acrophases of the serum PRL rhythm varied from 19:37 to 22:04 hr. Immunization decreased circulating LH and suppressed its 24-hr rhythmicity pattern. The effect of immunization on LH was counteracted by melatonin injection. Acrophases of serum LH rhythm varied from 00:44 to 03:53 hr. Significant effects of immunization and time of day on circulating insulin were detected; immunization increased serum insulin levels with a shift in acrophase from early afternoon to midnight. The data indicate that several early changes in levels and 24-hr rhythms of circulating ACTH, PRL, and LH in Freund's adjuvant-injected rats were sensitive to treatment with pharmacological amounts of melatonin.
Asunto(s)
Artritis Experimental/sangre , Ritmo Circadiano/efectos de los fármacos , Insulina/sangre , Melatonina/farmacología , Hormonas Hipofisarias/sangre , Hormona Adrenocorticotrópica/sangre , Análisis de Varianza , Animales , Hormona del Crecimiento/sangre , Hormona Luteinizante/sangre , Masculino , Prolactina/sangre , Ratas , Ratas WistarRESUMEN
The contribution of tuberohypophyseal and periventricular-hypophyseal dopaminergic neurons to the regulation of the secretion of prolactin (PRL) has yet to be clarified. In this study, we used pituitary stalk compression to disrupt hypothalamic neural input to the neurointermediate lobe (NIL). Neurointermediate lobe denervation (NIL-D) selectively disrupts the axons of tuberohypophyseal and periventricular-hypophyseal dopaminergic neurons, while leaving tuberoinfundibular dopaminergic neurons and the vascular supply of the pituitary gland intact. NIL-D was performed in ovariectomized (OVX) rats. The concentration of DA and 3,4-dihydroxyphenylacetic acid (DOPAC) in the median eminence (ME) and various regions of the pituitary gland of OVX and OVX+NIL-D rats were measured by HPLC-EC. The concentration of PRL, alpha-melanocyte stimulating hormone (alpha-MSH), and luteinizing hormone (LH) in serum were determined by radioimmunoassay. Successful NIL-D was confirmed by increased water intake. One week after NIL-D, serum PRL and alpha-MSH were elevated, but there was no change in the concentration of LH in serum. The concentration of DA was increased in the median eminence (ME), decreased in the outer zone of the anterior lobe (AL-OZ), as well as the intermediate (IL) and neural lobes (NL), and remained unchanged in the inner zone of the anterior lobe (AL-IZ). The concentration of DOPAC was increased in the ME and NL, decreased in the IL, and remained unchanged in both the AL-IZ and AL-OZ. These data confirm that pituitary stalk compression denervates the NIL. Moreover, decreases in the concentration of DA in the IL and AL-OZ, coupled with elevation of serum PRL and alpha-MSH indicate that DA from the NIL contributes to the increased inhibition of the secretion of PRL and alpha-MSH in OVX rats.
Asunto(s)
Dopamina/metabolismo , Hipotálamo/metabolismo , Fenómenos Fisiológicos del Sistema Nervioso , Neuronas/fisiología , Sistemas Neurosecretores/metabolismo , Neurohipófisis/inervación , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Desnervación , Ingestión de Líquidos/fisiología , Femenino , Hipotálamo/citología , Eminencia Media/metabolismo , Sistemas Neurosecretores/citología , Ovariectomía , Hormonas Hipofisarias/sangre , Ratas , Ratas Sprague-DawleyRESUMEN
Transcendental mediation (TM) is a stylized form of physical and mental relaxation which is associated with changes in the secretion and release of several pituitary hormones. The hormonal changes induced by TM mimic the effects of the inhibitory neurotransmitter gamma aminobutyric acid (GABA). It is hypothesized that TM produces changes in pituitary hormone secretion by enhancing hypothalamic GABAergic tone, and its anxiolytic effects by promoting GABAergic tone in specific areas of the brain. This mechanism is similar to the effects of synthetic anxiolytic and tranquilizing agents such as benzodiazepines that bind to components of the GABA-A (GABAA) receptor. TM, therefore, may produce relaxation by enhancing the effects of an endogenous neurotransmitter analogous to the effects of endorphins in runners who reportedly experience a 'runner's high'.
Asunto(s)
Hormonas Hipofisarias/sangre , Terapia por Relajación , Ácido gamma-Aminobutírico/fisiología , Arginina Vasopresina/sangre , Humanos , Hipotálamo/fisiología , Modelos Biológicos , Hormonas Hipofisarias/metabolismo , Prolactina/sangre , Receptores de GABA-A/fisiología , Estrés Fisiológico/sangre , Estrés Fisiológico/fisiopatología , Tirotropina/sangreRESUMEN
After bilateral superior cervical ganglionectomy (SCGx) of adult male rats, norepinephrine (NE) content of the medial basal hypothalamus (MBH) decreased significantly by 39-47% from 16 h to 7 days after surgery. During this time the levels of serum growth hormone (GH) and prolactin (PRL) and of MBH GH-releasing hormone (GRH), thyrotropin-releasing hormone (TRH) and somatostatin were measured by RIA. In sham-operated controls, serum PRL increased and serum GH decreased 16-24 h after surgery, attaining pre-surgical levels later on. In SCGx rats, significantly lower serum GH and PRL and higher MBH GRH and TRH content as compared to controls was observed 16-24 h after surgery, during the wallerian degeneration phase after SCGx. MBH somatostatin concentration decreased in SCGx rats 20 h after surgery. Two injections of the alpha 1-adrenoceptor blocker prazosin 45 and 90 min before sacrifice, alone or together with the beta-blocker propranolol, prevented the changes in MBH hypophysiotropic hormone content, as well as in serum GH and PRL levels, found in SCGx rats 20 h after surgery. Propranolol treatment did not affect hormone levels. Neither drug modified the decrease in MBH NE content observed after SCGx. The results argue in favor of the existence of physiologically relevant projections from superior cervical ganglion neurons to the MBH controlling hypophysiotropic hormone release.